PROCESSO PARA PREPARACAO DE NOVOS DERIVADOS DA 3,4-DIHIDRO-ISOQUINOLINA E DE COMPOSICOES FARMACEUTICAS QUE OS CONTEM

3,4-Dihydro-6,7-dimethoxy -1-(alpha-(bis(2-(2,3,4- trimethoxyphenyl)ethyl) -carbamoyl)benzyl)isoquinoline of formula (Ia) and its salts are new. Fused-ring dihydropyridine derivs. of formula (II) and their tautomers, salts and complexes are used as cerebroprotective agents, agents for treating chronic inflammatory disorders, and anticoagulants: X = OR1, NHR2 or NR3R4; R1 = H, 1-4C alkyl or 2-4C alkoxyalkyl; R2 = (a) e.g. H, 3-6C alkenyl, or (b) e.g. 1-6C alkyl opt. substd. by e.g. halogen, CN, OH, SH, 1-4C alkoxy; R3 and R4 = 1-4C alkyl opt. substd. by Ar2 or NR3R4 is a satd. or partially satd. opt. substd. 5- or 6-membered ring, opt. contg. up to two further heteroatoms (N, O and/or S): Ar1, Ar2 and R5 = phenyl opt. substd. by e.g. halogen, 1-4C alkoxy; Het = indolyl or 5- or 6-membered opt. substd. heterocyclyl contg. 1-3 heteroatoms (N, O and/or S); A = a gp. of formula A1-A4;: R5 is e.g. H, 1-4C alkyl; R6 and R7 is H, OH or R6+R7 = O(CH2)nO; R9 = H or 1-4C alkyl; R10 = H or 2-phenyl-2-ethoxycarbonylacetyl. Cpds. (I), other than (Ia), are described in EP 37934 and 251194.